Comparative Pharmacology
Head-to-head clinical analysis: Q PAM versus UROXATRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: Q PAM versus UROXATRAL.
Q-PAM vs UROXATRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
Selective antagonist of postsynaptic alpha1A-adrenoceptors in the prostate, bladder base, and prostatic urethra, leading to relaxation of smooth muscle and improved urinary flow.
100 mg orally twice daily
10 mg orally once daily, immediately after the same meal each day.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
The terminal elimination half-life is approximately 5 to 9 hours in healthy young subjects, and 6 to 10 hours in elderly patients. This supports once-daily dosing, with steady state achieved after 3-5 days.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
After oral administration, approximately 11% of the dose is excreted unchanged in urine, while 49% is excreted as metabolites in urine and 22% in feces. Overall, renal elimination accounts for about 60% of total clearance.
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker